ere  we offer access to some of our recent publications,  including the Dis-
cussion Paper series  issued by our Institute.  For some further publications
and presentations, you may also wish to visit the personal homepages of the
founders of the Institute.

Discussion Papers

Forthcoming:

• M. Schlander, G.-E. Trott, O. Schwarz:
  Estimating the cost of attention-deficit/hyperactivity disorder (ADHD) in Germany
  [Available in German: Wie teuer sind Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörungen für die Gesetzliche Krankenversicherung in Deutschland?]
  
  Discussion Paper No. 11 / 2009
  ISBN 978 3 941609 10 5
  
  
  
• M. Schlander, J. Meyer:
  Comparative Evaluation of Medical Technologies: NICE Lessons from Europe.
  
  Discussion Paper No. 10 / 2009
  ISBN 978 3 941609 09 9
  
  
  

Available:

• M. Schlander:
  Comparative Effectiveness Programs: A Global Perspective, Discussing Germany and the United Kingdom. Briefing Document for The Galen Institute, Washington, DC
  
  Discussion Paper No. 09 / March 2009
  ISBN 978 3 941609 08 2
  
  
  
• M. Schlander, O. Schwarz, A. Rothenberger, V. Roessner:
  Tic disorders: prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample.
  
  Discussion Paper No. 08 / January 2009
  ISBN 978 3 941609 07 5
  
  
  
• M. Schlander:
  In Search of Efficiency
  [Available in German: Der Effizienz auf der Spur]
  
  Discussion Paper No. 07 / July 2008
  ISBN 978 3 941609 06 8
  
  
  
• M. Schlander:
  House of Commons Health Committee Inquiry into aspects of the work of the National Institute for Health and Clinical Excellence.
  
  Discussion Paper No. 06 / May 2007
  ISBN 978 3 941609 05 1
  
  
  
• C. Thielscher, M. Schlander:
  How Much Glasnost for German Health Care?
  [Available in German: Wieviel Glasnost braucht das deutsche Gesundheitswesen?]:
  
  Discussion Paper No. 05 / January 2007
  ISBN 978 3 941609 04 4
  
  
  
• M. Schlander:
  That Infamous Fourth Hurdle: Ten Things to Consider When Regulating Reimbursement of New Drugs in Germany
  [Available in German: Rationaler Umgang mit neuen Medikamenten: Zehn Thesen zur geplanten „Vierten Hürde“ für neue Arzneimittel]
  
  Discussion Paper No. 04 / November 2006 (2nd edition)
  ISBN 978 3 941609 03 7
  
  
  
• M. Schlander:
  Long-Acting Medications for the Hyperkinetic Disorders: A Note on Cost-Effectiveness.
  
  Discussion Paper No. 03 / September 2006
  ISBN 978 3 941609 02 0
  
  
  
• M. Schlander:
  Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on Prescription Drug Spending for Children and Adolescents: Increasing Relevance of Health Economic Evidence
  
  Discussion Paper No. 02 / June 2006
  ISBN 978 3 941609 01 3
  
  
  
• M. Schlander, C. Thielscher, O. Schwarz:
  Affordable Health Care Expenditure and Real Economic Growth
  
  Discussion Paper No. 01 / July 2005
  ISBN 978 3 941609 00 6
  
  
  

Monographs

Forthcoming:

• M. Schlander (ed.):
  Economic Evaluation of Health Care Programs:
  Current Concepts, Controversies, and International Experience.
  Springer, New York, NY (scheduled to appear in 2009)
  
  With contributions by Friedrich Breyer, Bernd Brüggenjürgen, Martin J. Buxton, J. Jaime Caro, Sören Holm, Panos G. Kanavos, Mathias Kifmann, Peter Kolominsky-Rabas, Weyma Lübbe, Deborah Marshall, John McKie, Peter J. Neumann, Erik Nord, Ulf Persson, Gérard de Pouvourville, Michael Schlander, Jean Sullivan, Darcey Terris, Koen Torfs, Rosalie Viney, Stefan Willich, and others.
  
  

Available:

• M. Schlander:
  Health Technology Assessments by the National Institute for Health and Clinical Excellence (NICE): A Qualitative Study.
  Springer, New York, NY, 2007 (245 pages)
  
  ISBN 978 0 387 71995 5
  Library of Congress Control Number: 2007926599